Autolus Therapeutics received conditional marketing authorization in Europe on August 13, 2025, alongside a related CMS decision on split reimbursement.
2 reports, 2 independent
Updated Aug 13
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Autolus Therapeutics received conditional marketing authorization in Europe on August 13, 2025, alongside a related CMS decision on split reimbursement.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Europe
terrestrial continent located in north-western Eurasia
-
Autolus Therapeutics
company in London, United Kingdom
Nothing else this week.
-
CMS
International law firm
Coverage
Newest first; wire copies grouped- GuruFocus.comAutolus Therapeutics PLC (AUTL) Q2 2025 Earnings Call Highlights: Strong Product Sales Amid ... Net Product Revenue: $20.9 million for Q2 2025, up from $9 million in Q1 2025. Cost of Sales: $24.4 mil
- GlobeNewswireAutolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 20